Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02089789 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 174 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Re-verified, no change to tracked fields
  2. Minor Eligibility criteria shortened, about 1 word
  3. Minor Study description shortened, about 36 words
  4. Minor Secondary endpoints: details revised at 1 of 1 entry Eligibility criteria expanded, about 4 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words
  5. Minor 28 versions Re-verified since Feb 6, 2025, no change to tracked fieldsv143-v170
Show 18 earlier versionsHide 18 earlier versions
  1. Minor Eligibility criteria revisedv142 See this version in full on ClinicalTrials.gov ↗
  2. Minor Enrollment target: 150 to 200v141
  3. Notable Primary and study completion dates: Dec 1, 2024 to Dec 1, 2030 Site contact updatedv140 Show 1 more changeShow less
    • Site contact updated
  4. Minor 5 versions Re-verified since Jan 10, 2024, no change to tracked fieldsv135-v139
  5. Notable Primary and study completion dates: Dec 1, 2023 to Dec 1, 2024v134
  6. Minor 5 versions Re-verified since Dec 15, 2022, no change to tracked fieldsv129-v133
  7. Minor Study Status, Contacts/Locationsv128
  8. Minor 3 versions Re-verified since Jul 1, 2022, no change to tracked fieldsv125-v127
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: \- Proteins, fats, and other molecules are the body s building blocks. Many of these molecules must have sugars, or chains of sugars, attached to work properly. People with congenital disorders of glycosylation (CDGs) cannot attach these sugars or sugar chains properly. A child or adult with a CDG can have symptoms in different parts of the body, including brain, nerves, muscles, liver, and immune system. Researchers want to learn more about these diseases to understand better what is causing the problems. Objective: \- To learn more about CDGs. Eligibility: \- People 1 month to 2 years old may be seen as outpatients or by telehealth. Patients 2-80 years with CDG or suspected to have a CDG may be seen under this protocol as inpatients, outpatients or by teleheath. Design: * CDG participants may be seen as inpatients, outpatients or by teleheath. Inpatient stays may last 2-5 days. * They will have:-Medical history and physical exam. They will answer questions about their CDG. * Blood taken several times. Their skin will be numbed, then a needle will take blood from an arm vein. * Samples taken of their skin, urine, and maybe stool and spinal fluid. * Photos taken of their whole body. They can wear underwear and cover their eyes. * Brain MRI. They will lie on a table that slides in and out of a metal cylinder. The scanner makes loud knocking noises so they can wear earplugs. * Abdomen ultrasound. Sound waves take images of the body from the outside. * Hand/wrist X-rays for young patients. They may have a full-body X-ray. * DEXA bone density scan. Participants will lie on a table under a scanner. * Echocardiogram and electrocardiogram for heart activity. Pads are stuck on the skin and the electrical activity of the heart is recorded. * Tests of hearing, thinking, motor skills, and speech. * Children participants may have tests done under sedation if it will benefit them directly. * CDG participants may have other procedures during their visit. They may have follow-up visits every year.
Trial Details
NCT Number NCT02089789
Lead Sponsor National Human Genome Research Institute (NHGRI)
Conditions Congenital Disorders of Glycosylation
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov